Tech Company Financing Transactions
Cardioxyl Pharmaceuticals Funding Round
On 8/2/2010, Cardioxyl Pharmaceuticals landed $15 million in investment from Aurora Funds and New Enterprise Associates.
Transaction Overview
Company Name
Announced On
8/2/2010
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Undisclosed
Investors
Aurora Funds (Jeffrey Clark)
New Enterprise Associates (James Barrett)
Proceeds Purpose
With this additional funding, Cardioxyl is well capitalized to execute on a Phase IIa trial for CXL-1020 and to continue development of our promising research portfolio.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1450 Raleigh Rd. 212
Chapel Hill, NC 27517
USA
Chapel Hill, NC 27517
USA
Phone
Website
Email Address
Overview
Cardioxyl Pharmaceuticals' mission is the discovery and development of newclasses of safe and effective therapeutic agents for the treatment ofcardiovascular disease. Cardioxyl's initial program is a novel medication forthe treatment of acute decompensated heart failure.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christopher Kroeger
Chief Medical Officer
Shi Foo
Chief Scientific Officer
John Reardon
VP - Regulatory Affairs
Doug Cowart
Browse more venture capital transactions:
Prev: 8/2/2010: Avedro venture capital transaction
Next: 8/2/2010: mFoundry venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs